Pfizer 2006 Annual Report Download - page 21

developments with respect to certain patent litigation relating
to Detrol/Detrol LA.
•
Camptosar is indicated as first-line therapy for metastatic
colorectal cancer in combination with 5-fluorouracil and
leucovorin. It is also indicated for patients in whom metastatic
colorectal cancer has recurred or progressed despite following
initial fluorouracil-based therapy. Camptosar is for intravenous
use only. Revenues of $903 million in 2006 were comparable to
2005. The National Comprehensive Cancer Network (NCCN), an
alliance of 20 of the world’s leading cancer centers, has issued
guidelines recommending Camptosar as an option across all
lines of treatment for advanced colorectal cancer.
•
Sutent is an oral multi-kinase inhibitor that combines anti-
angiogenic and anti-tumor activity to inhibit the blood supply
to tumors and has direct anti-tumor effects. Sutent was
approved by the FDA and launched in the U.S. in January 2006
for advanced renal cell carcinoma, including metastatic renal
cell carcinoma, and gastrointestinal stromal tumors (GIST) after
disease progression on or intolerance to imatinib mesylate.
Since approval, Sutent has been used to treat more than 7,500
patients in the U.S. In January 2007, Sutent received full
marketing authorization and extension of the indication to first-
line treatment of advanced and/or metastatic renal cell
carcinoma (mRCC), as well as approval as a second-line
treatment for GIST, in the E.U.
Data from a first-line Phase 3 trial was published in the
January 11, 2007, New England Journal of Medicine, in which
Sutent doubled progression-free survival versus interferon-
alpha (11 months vs. 5 months). In November 2006, the NCCN
published updated kidney cancer guidelines, confirming Sutent
as an appropriate first-line therapy. In its other core indication,
Sutent is the first approved agent to show a clinical benefit after
imatinib failure in GIST. As reported in the October 10, 2006,
issue of The Lancet, Sutent treatment produced a four fold
increase in median time to tumor progression vs. placebo (27.3
weeks vs. 6.4 weeks). Sutent has received approvals or
registration in several countries in Asia and Latin America and
is expected to launch in many more markets worldwide in
2007. Sutent recorded $219 million in sales worldwide in 2006
and had been used to treat more than 15,000 patients as of
December 2006.
•
Xalatan/Xalacom, a prostaglandin analogue used to lower the
intraocular pressure associated with glaucoma and ocular
hypertension, is the most-prescribed branded glaucoma
medicine in the world. Clinical data showing its advantages in
treating intraocular pressure compared with beta blockers
should support the continued growth of this important
medicine. Xalacom, the only fixed combination prostaglandin
(Xalatan) and beta blocker, is available primarily in European
markets. Xalatan/Xalacom sales grew 6% in 2006 compared to
2005.
•
Zyrtec provides strong, rapid and long-lasting relief for seasonal
and year-round allergies and hives with once-daily dosing.
Zyrtec continues to be the most-prescribed antihistamine in the
U.S. in a challenging market. Sales increased 15% in 2006
compared to 2005. In February 2006, we began a new DTC
advertising campaign featuring new insight that allergy
symptoms can worsen over time due to exposure to new
allergens. We will lose U.S. exclusivity for Zyrtec in December
2007. Since we sold our rights to market Zyrtec over-the-
counter in connection with the sale of our Consumer Healthcare
business, we expect no revenue from Zyrtec after the expiration
of the U.S. patent in December.
•
Alliance revenues reflect revenues primarily associated with our
co-promotion of Aricept, Macugen, Rebif and Spiriva.
—Aricept, discovered and developed by our alliance partner
Eisai Co., Ltd, is the world’s leading medicine to treat
symptoms of Alzheimer’s disease.
—Macugen, discovered and developed by our alliance partner
OSI Pharmaceuticals, Inc. (OSI), is for the treatment of AMD.
We are in negotiations with OSI to return the U.S. rights to
Macugen to OSI in exchange for a royalty-free license to
market Macugen outside the U.S.
—Rebif, discovered and developed by Serono S.A. (Serono), is
used to treat symptoms of relapsing forms of multiple
sclerosis. Pfizer co-promotes Rebif with Serono in the U.S.
—Spiriva, discovered and developed by our alliance partner
Boehringer Ingelheim (BI), is used to treat chronic obstructive
pulmonary disease, a chronic respiratory disorder that
includes chronic bronchitis and emphysema.
Alliances allow us to co-promote or license these products for
sale in certain countries. Under the co-promotion agreements,
these products are marketed and promoted with our alliance
partners. We provide funding through cash, staff and other
resources to sell, market, promote and further develop these
products.
Product Developments
We continue to invest in R&D to provide future sources of revenues
through the development of new products, as well as through
additional uses for existing in-line and alliance products. We
have a broad and deep pipeline of medicines in development.
However, there are no assurances as to when, or if, we will receive
regulatory approval for additional indications for existing products
or any of our other products in development. Below are significant
regulatory actions by, and filings pending with, the FDA and
other regulatory authorities.
2006 Financial Report 19
Financial Review
Pfizer Inc and Subsidiary Companies